510(k) · Cleared
Recalled · 2010Modification to Mammaprint
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Agendia BV · NYI Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer
Cleared on Jul 21, 2008 as substantially equivalent to K070675 (Agendia BV, 2007) after a 172-day review. Its family tree reaches back 2 generations to 2007. 7 later devices descend from it. It has been recalled once.
- Decided
- Jul 21, 2008
- Review
- 172 days
- Class
- Class II
- Product code
- NYI
- Recalls
- 1
- Predicates
- 1
Its longest line of descent runs back 2 generations to DEN070009 (2007). 7 later devices descend from it, 1 citing it directly.
- Root · 2 generations backDEN070009 MammaprintAgendia BV · 2007
- 1 generation backK070675 MammaprintAgendia BV · 2007 · Recalled
- This deviceK080252 Modification to MammaprintAgendia BV · 2008
- Descendant · cites it directly · 6 of its ownK081092 Modification to MammaprintAgendia · 2009 · Recalled
- Descendant · 2 generations on · 3 of its ownK101454 MammaprintAgendia · 2011
- Descendant · 3 generations on · 2 of its ownK141142 Mammaprint FfpeAgendia · 2015
- Descendant · 4 generations on · 1 of its ownK201902 MammaPrintAgendia, Inc. · 2020
- Descendant · 2 generations on · 1 of its ownK130010 Prosigna (TM) Breast Cancer Prognostic Gene Signature AssayNanostring Technologies · 2013
Showing 5 of 7 descendants. See all descendants
Descendants cleared per year
Most influential descendants
Showing 5 of 7 · See all- K081092Modification to MammaprintAgendia · 2009 · cites it directly6descendants
- K101454MammaprintAgendia · 2011 · 2 generations on3descendants
- K141142Mammaprint FfpeAgendia · 2015 · 3 generations on2descendants
- K201902MammaPrintAgendia, Inc. · 2020 · 4 generations on1descendant
- K130010Prosigna (TM) Breast Cancer Prognostic Gene Signature AssayNanostring Technologies · 2013 · 2 generations on1descendant
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −2 | DEN070009 | Mammaprint | Agendia BV | 2007 | — |
| −1 | K070675 | Mammaprint | Agendia BV | 2007 | 1 |
| 0 (this device) | K080252 | Modification to Mammaprint | Agendia BV | 2008 | — |
| +1 | K081092 | Modification to Mammaprint | Agendia | 2009 | 1 |
| +2 | K101454 | Mammaprint | Agendia | 2011 | — |
| +3 | K141142 | Mammaprint Ffpe | Agendia | 2015 | — |
| +4 | K201902 | MammaPrint | Agendia, Inc. | 2020 | — |
| +2 | K130010 | Prosigna (TM) Breast Cancer Prognostic Gene Signature Assay | Nanostring Technologies | 2013 | — |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2009 | 1 | 0 |
| 2011 | 1 | 0 |
| 2013 | 1 | 0 |
| 2014 | 1 | 0 |
| 2015 | 1 | 0 |
| 2020 | 1 | 0 |
| 2022 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in NYI? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new NYI device
- #1 K210973 MammaPrint FFPE NGS Kitscore 5.8 · 7 generations · no Class I recall
- #2 Held for the reportin the report
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K070675 | MammaprintSummary page 1…ame Multivariate device for cancer prognosis 8. Classification Class II,regulated under 21 CFR 866.6040, product code NYI 9. PredicateDevice Agendia BV's MammaPrint (k070675) Agendia BV - Amsterdam 2008 - 0801 Additional Scanner… | 2007 |
What descends from it? (7)
1 later device cites it directly; ranked here by how many devices descend from each in turn.
| Number | Device | Decided | Descendants |
|---|---|---|---|
| K081092 | Modification to Mammaprint | 2009 | 6 |
Has anything in its family been recalled? (0 Class I)
Recalls of this device
| Date | Class | Recall | Root cause | Reason |
|---|---|---|---|---|
| Mar 3, 2010 | Not classified | Z-1321-2010 | Other | Over a period of about 6 months in about 15% of results provided Agendia has been "over reporting" the chance of metastasis risk being 29% risk of recurrence instead of 10% risk. This over reporting of risk did not cause direct injury to… |
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 1 year and passes through 1 company; a new generation was cleared every 1.1 years on median.
- 1 of the 2 ancestors has a recall of any class.
- Of its descendants, K081092 (Agendia, 2009) has gone furthest, with 6 descendants of its own.
How does its category compare?
All NYI devicesNYI Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer: FDA decisions, review times, recalls and adverse event reports over 20 years. 2008, this device’s year, is highlighted.
FDA decisions per year · NYI
1in 2022
2026 to Oct 25, outlined.
Median 510(k) review, days · NYI
Too few NYI 510(k)s in any year since 2007 to give a median.
Recalls per year · NYI
1in 2010
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · NYI
1in 2023
MAUDE reports naming product code NYI, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 2 | — | 0 | 0 |
| 2008 | 1 | — | 0 | 0 |
| 2009 | 1 | — | 0 | 0 |
| 2010 | 0 | — | 1 | 0 |
| 2011 | 1 | — | 0 | 0 |
| 2012 | 0 | — | 0 | 0 |
| 2013 | 1 | — | 0 | 0 |
| 2014 | 1 | — | 0 | 0 |
| 2015 | 1 | — | 0 | 0 |
| 2016 | 0 | — | 0 | 0 |
| 2017 | 0 | — | 0 | 0 |
| 2018 | 0 | — | 0 | 0 |
| 2019 | 0 | — | 0 | 0 |
| 2020 | 1 | — | 0 | 0 |
| 2021 | 0 | — | 0 | 0 |
| 2022 | 1 | — | 0 | 0 |
| 2023 | 0 | — | 0 | 1 |
| 2024 | 0 | — | 0 | 0 |
| 2025 | 0 | — | 0 | 0 |
| 2026 | 0 | — | 0 | — |
What is it indicated for?
MammaPrint is a qualitative in vitro diagnostic test service, performed in a single laboratory, using the gene expression profile of fresh breast cancer tissue samples to assess a patients' risk for distant metastasis.
The test is performed for breast cancer patients who are less than 61 years old, Stage I or Stage II disease, with a tumor size of - 5.0 cm and lymph node negatfe. The MammaPrint result is indicated for use by physicians as a prognostic marker only, along with a other clinicopathological factors.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K080252 · printed Nov 3, 2026
Cite this page
510(k) Report. “K080252: Modification to Mammaprint.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 3, 2026. https://510kreport.com/device/K080252
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026